Jun
26
Japan Approves First Generic Biotech HGH Drug
June 26, 2009 | Leave a Comment
ZURICH, June 25 (Reuters) - Japanese regulators approved a human growth hormone from Novartis AG, the first green light in Japan for a biosimilar or generic version of a biotech drug, the Swiss drugmaker said on Thursday
Biosimilars are viewed as a promising new market, given the pent-up demand for cheaper versions of extremely expensive biotech drugs, some of which are coming to the end of their patent life.
Somatropin, made by Novartis’ generics unit Sandoz, is for treatment of growth hormone deficiency in children and growth disturbance associated with Turner’s syndrome or chronic renal insufficiency, the group said.
May
8
Here is an excerpt from one mother’s struggle as she raises a daughter with Turner’s Syndrome.
Why is my daughter small for her age? Does she take after my side of the family? Might there be something wrong? These nagging questions were easily dismissed. My daughter appeared to be a typical, healthy and happy petite child.
With a diagnosis of Turner syndrome, time is of the essence to achieve optimum vertical growth. Dr. Henry Anhalt, DO, FAAP, FACOP, FACE, CDE, Pediatric and Adolescent Endocrinology and Diabetes, Hackensack, NJ, became our TS specialist. He ordered a battery of testing for bone age, cardiac, hearing, kidneys and ovaries. After a complete and thorough evaluation, we began treatment with daily injections of human growth hormone (hgh).
Recommended Links
GET YOUR FREE HGH &
ANTI-AGING REPORT!
- Get your own FREE copy of the groundbreaking report, "Seven Age Reversing Secrets" – packed with valuable tips and tricks to help you fight the aging process and have the highest quality of life possible!